Compremium's Non-Invasive CVP Device Receives FDA Breakthrough Designation
Key Insights
Compremium AG received FDA Breakthrough Device Designation for its Quantis CVP (search) system, a non-invasive technology designed to directly measure central venous pressure (search) without catheterization.
The device also joined the FDA's Total Product Life Cycle Advisory Program (TAP), which provides coordinated regulatory engagement and accelerated development pathways.
Early clinical studies demonstrated promising correlation between non-invasive measurements and invasive catheter readings across clinically relevant pressure ranges with rapid, reproducible results.
Compremium AG announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation to its Quantis CVP (search) system, a novel non-invasive technology designed to directly measure central venous pressure (search). The Swiss medical technology company's device has also been accepted into the FDA's Total Product Life Cycle Advisory Program (TAP), providing accelerated regulatory pathways for this critical hemodynamic monitoring solution.
Addressing Critical Clinical Needs
Volume assessment is critical for hemodynamic management of patients requiring close monitoring across acute conditions such as sepsis (search), shock (search), heart failure (search), venous congestion (search), and fluid under- or overload. The current gold standard relies on central venous pressure (search) measured invasively with catheterization, which carries significant risks including infection (search) and thrombosis (search).
Compremium Quantis CVP (search) offers a non-invasive alternative designed for use in both adult and pediatric patients at the bedside. Early clinical studies demonstrated promising correlation between non-invasive measurements and invasive catheter readings across clinically relevant pressure ranges. The measurements were rapid, reproducible, and achievable with limited operator training.
Regulatory Pathway and Development Strategy
"Receiving Breakthrough Device Designation and joining the FDA's Total Product Life Cycle Advisory Program reflects both the clinical importance of the unmet medical need we are addressing and the rigor of our development approach," said Vincent Baumann, chief executive officer of Compremium. "These programs allow us to de-risk the development and shorten the time to market for Quantis CVP (search) while strengthening our path toward clinical adoption through early engagement with FDA experts, clinicians, and payers."
The FDA's Breakthrough Devices Program is designed to expedite the development and review of technologies that may offer more effective diagnosis or treatment of serious conditions. The TAP Program provides coordinated FDA engagement across the product life cycle, including regulatory strategy and interactions with clinicians and payers.
Technology Platform and Market Context
Compremium Quantis CVP (search) is built on Compremium's established platform, components of which are already FDA-cleared and CE-marked for another clinical application. The company's technology has been evaluated in more than 40 clinical studies, with its lead commercial product, Compremium Quantis® ST (search), already FDA-cleared and CE-marked for soft-tissue assessment.
The announcement comes amid broader advances in noninvasive hemodynamic monitoring, a sector that has drawn increasing attention as hospitals seek safer, faster and more cost-effective ways to manage critically ill patients. Device developers have made progress in using ultrasound, wearable sensors and advanced signal-processing algorithms to estimate cardiovascular parameters that previously required invasive lines.
The push toward noninvasive solutions has been further fueled by staffing shortages and infection (search)-control concerns. Technologies that require less specialized training and reduce the need for central lines can help lower complication rates and free up clinical resources, particularly in high-acuity settings.